Serum transaminase (AST and ALT) values were monitored after administration of placebo to 104 healthy male volunteers for a phase I study. Both values remained within normal ranges in most of them. However, AST or ALT was above the normal range in 13 volunteers (12.5%) . Their clinical features were ALT>AST, high serum rglutamyl trans peptidase, high serum triglyceride, high obesity index, or a combination of any of the four. We concluded that AST or ALT is likely elevated in volunteers showing these clinical signs; this should be noted in the evaluation of drug toxicity in future phase I studies.
Introduction
Phase I studies of new drugs typically include "healthy" male volunteers in whom all clinical examination results are within normal ranges.
Placebos or pharmacologically inactive compounds are also administered as the control in these studies. However, we found that serum AST (aspartate aminotransferase, GOT) or ALT (ala nine aminotransferase, GTP) was above the nor mal range in some volunteers after the admin istration of placebo. These enzyme levels might have a wide intraindividual variation in volun teers under physiological or normal conditions.
We investigated the clinical characteristics of these volunteers in whom AST or ALT was elevated to determine whether or not this eleva tion could be predicted from any clinical tests.
Subjects and Methods
We studied 104 male volunteers who received a single or multiple (maximum 7 times) admini stration of placebo for phase I studies in the Kitasato University East Hospital. All of the volunteers gave informed consent, and the studies were permitted by the Institutional Review Board. 
